Pharma major Cipla posted a 5.97 per cent year-on-year rise in net profit to Rs 478.19 crore in the June quarter and 1.26 per cent rise in sales to Rs 3,894.46 crore. EBITDA margin for the quarter stood at 22.7 per cent. Speaking to BTVI, Kedar Upadhye, Joint President and Global CFO at Cipla, said launch of Cinacalcet led to improvement in margins. He said the firm is working towards 10-12 meaningful launches in US generic market. Here's more.